{"id":4709,"date":"2014-06-04T13:14:12","date_gmt":"2014-06-04T13:14:12","guid":{"rendered":"\/?p=4709"},"modified":"2014-06-04T13:14:18","modified_gmt":"2014-06-04T13:14:18","slug":"itonis-inc-otcmktsitns-gets-a-400k-pump","status":"publish","type":"post","link":"\/articles\/itonis-inc-otcmktsitns-gets-a-400k-pump\/","title":{"rendered":"ITonis Inc (OTCMKTS:ITNS) Gets a $400K Pump"},"content":{"rendered":"

\"0ITNS.png\"If you open ITonis Inc (OTCMKTS:ITNS<\/a>)’s latest financial report and scroll down to the Loan Payable section (Note 5 on Page 22), you’ll see that last year, the company received $114,454 in short-term loans from a few unnamed parties. You’ll also see that during the quarter ended February 28, 2014, ITNS<\/a><\/strong> converted $31,500<\/strong> of these loans into 106,333,333 shares of common stock<\/strong>. <\/p>\n

Yesterday, ITNS<\/a><\/strong> got pumped by Stock Freak (who disclosed a $400 thousand compensation) and as a result, the ticker managed to shift nearly 48 million shares. <\/p>\n

Is there a connection between the promotion and the conversion of debt? We’ll probably never know.<\/p>\n

The truth is, people don’t seem too bothered about the pump. The ticker’s performance yesterday wasn’t exactly consistent, but it did close the session almost 30% above its previous value. ITNS<\/a><\/strong> is now comfortably above the $0.01 per share barrier and it seems like it has enough steam to push even further up.<\/p>\n

The company issued a press release after Monday’s closing bell which further boosted the effects of the promotional campaign. ITNS<\/a><\/strong> said that the FDA have given their final approval for the Emesyl® homeopathic product for nausea relief. Apparently, all ITNS<\/a><\/strong> need to do now is come up with the final packaging design and put it into production. That is a major milestone for the company and it should mean that the future financial statements will finally contain some figures in the revenues section.<\/p>\n

Investors know that and they are understandably excited about the developments. There are, however, a few things that need to be considered carefully.<\/p>\n

If you’ve been following our articles closely, you’ll know that INTS<\/strong>‘ financial statements have never really been that good and unfortunately, the latest one is no exception to the rule. Here are the figures as recorded on February 28:<\/p>\n